We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It is looking increasingly likely that the Indian government will
intervene to halt a reported price war between Indian exporters of APIs and generic drugs to the US$5bn African drug market.
Strand Life Sciences, a Bangalore-based in silico technologies company announced today that it has entered into a research collaboration with Elan Pharmaceuticals aimed towards supporting Elan's drug discovery efforts.
PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS) today announced that it has received marketing authorization for Plenaxis(R) (abarelix 100 mg powder for an injectable suspension) from the German competent authority, Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM).
Generex Biotechnology Corporation (Nasdaq: GNBT), a leader in the area of buccal drug delivery, announced today that it has initiated a scale-up commercial production run of Oral-lyn(TM), the Company's proprietary oral insulin buccal spray product.
Dainippon Pharmaceutical Co., Ltd (Headquarters: Osaka, President: Kenjiro Miyatake) and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) today signed an exclusive licensing agreement for AS-3201 (generic name: ranirestat), an investigational drug for the treatment of diabetic neuropathy that was discovered and is being developed by Dainippon Pharmaceutical.
Dr. Reddy's Laboratories (NYSE: RDY) announced today that the Company has entered into a co-development and commercialization agreement with Denmark based Rheoscience A/S for the joint development and commercialization of balaglitazone (DRF 2593), a partial PPAR-gamma agonist, for the treatment of type 2 diabetes.
Merck KGaA, which sells the Erbitux tumor treatment in Europe, will get a 60-million-euro ($72.4 million) payment from Takeda Pharmaceutical Co. as the companies develop an experimental medicine for several types of cancer.
Pharma Israel, which represents research-based multinationals in the country, has called for the government to reverse its lax new patent law, claiming such a move would boost foreign investment in clinical trials by US$200mn per year.